AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca raised its full-year sales guidance on strength from its Covid drugs, leading AZN stock to inch higher early Friday. The post AstraZeneca Boosts 2022 Sales Outlook, Citing Covid Treatments appeared first on Investor's Business Daily.

AstraZeneca Boosts 2022 Sales Outlook, Citing Covid Treatments

Long-serving AstraZeneca boss Pascal Soriot said on Friday he expects to work with the new chairman-designate of the London-listed drugmaker, who will take over in 2023, for many years to come, suggesting he is not ready to retire.

AstraZeneca CEO Soriot says to work with new chairman for many years

AstraZeneca PLC (LSE:AZN) followed its smaller rival GSK PLC (LSE:GSK, NYSE:GSK) by upgrading guidance for the full year after a bumper first half which exceeded expectations. The key driver for the outperformance appears to be sales of the group's Covid vaccine, which was jointly developed with the University of Oxford.

AstraZeneca follows the trend in the sector to upgrade guidance as Covid vaccines sales show resilience

AstraZeneca on Friday topped analyst expectations for second-quarter profit and revenue, helped by higher demand for its cancer medicines.

AstraZeneca beats Q2 profit and revenue estimates

Strong demand trends for AstraZeneca's (AZN) key drugs, Lynparza, Tagrisso, Imfinzi and Farxiga are likely to have driven the top line in the second quarter.

Will AstraZeneca (AZN) Deliver a Beat This Earnings Season?

AstraZeneca announced looming approval for two drugs in Europe and an FDA review for a third med, leading AZN stock to inch higher Monday. The post AstraZeneca Eyes A Trio Of Drug Approvals And Maybe A Breakout appeared first on Investor's Business Daily.

AstraZeneca Eyes A Trio Of Drug Approvals And Maybe A Breakout

AstraZeneca will announce Q222 earnings this Friday, July 29. The company has driven >90% share price growth over the past five years.

AstraZeneca: Q2 2022 Earnings May Not Wow Investors - Steady Growth's The Charm

AstraZeneca PLC (LSE:AZN) on Monday revealed why it is considered to have one of the strongest drug pipelines in the life sciences industry with three major announcements in the space of five minutes. In stock exchange missives the Anglo-Swedish giant said it had been granted a US priority review that would pave the way for the use of its treatment Enhertu in women with the HER-2 form of breast cancer.

AstraZeneca delivers a triple dose of drug updates

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low Metastatic Breast Cancer

ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low Metastatic Breast Cancer

Incyte

Their drug prospects are helping them perform better than most stocks on the market this year.

2 Unstoppable Stocks Set to Keep Beating the Market in 2022

AstraZeneca (AZN) and partner Daiichi Sankyo's cancer drug, Enhertu, receives EU approval for use in adults with unresectable or metastatic HER2-positive breast cancer.

AstraZeneca (AZN) Enhertu Receives EU Nod for Expanded Use

Merck

Merck & Co Inc (NYSE: MRK) will stop for futility the Phase 3 LYNK-003 trial of Lynparza with or without bevacizumab for unresectable or metastatic colorectal cancer who have not progressed following first-line induction.  The action follows the recommendation of an.

Merck & AstraZeneca Partnered Lynparza Fails In Late-Stage Colorectal Cancer Study

TOKYO & MUNICH, Germany--(BUSINESS WIRE)--ENHERTU® Approved in the EU for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens

ENHERTU® Approved in the EU for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens

AstraZeneca's operating income was $2,808 million in Q1 2022, up 49.5% QoQ. At the end of June 2022, the CHMP recommended the approval of Enhertu and Lynparza in the EU.

AstraZeneca: Lifeline Amid Double-Digit Inflation

Eli Lilly

Pfizer

Regeneron Pharmaceuticals

Roche Holding AG

Sanofi

Health care investors would be wise to keep tabs on the results of numerous drug trials scheduled to be revealed in the third quarter. Trial data can impact the stock price of a pharmaceutical company, sometimes sending it up, sometimes down.

3rd-Quarter Clinical Trial Data Could Shake Up Pharma Stocks

AstraZeneca's (AZN) acquisition of TeneoTwo is set to add an early-stage T-cell engager to AZN's pipeline. The transaction is likely to close by third-quarter 2022.

AstraZeneca (AZN) to Buy TeneoTwo, Boost Hematology Pipeline

AstraZeneca has agreed to buy biotech firm TeneoTwo in a deal worth up to $1.27, with Non-Hodgkin's lymphoma early-stage treatment at the heart of the deal.

AstraZeneca to buy biotech firm TeneoTwo for up to $1.27 billion

Anglo-Swedish drugmaker AstraZeneca (NASDAQ: AZN), announced on July 5, that they will acquire biotechnology firm TeneoTwo. The deal will be.

Two vaccine stocks making headlines worth keeping an eye on

AstraZeneca said on Tuesday it will acquire oncology firm TeneoTwo Inc in a deal worth up to $1.27 billion, including the company's initial stage T-cell engager.

AstraZeneca to buy oncology firm TeneoTwo for up to $1.27 billion

AstraZeneca PLC (LSE:AZN) has struck a deal to swallow up a US-based owner of potential new drug cancer medicines for an initial U$S100mln (£82.6mln) and up to US$1.06bn in milestone payments. The FTSE 100 company said it has agreed to buy TeneoTwo Inc and its main drug assets, which include TNB-486, which is a type of an emerging class of therapeutic antibodies known as T-cell engagers.

AstraZeneca acquires blood cancer specialist TeneoTwo for up to US$1.2bn

Britain's Oxford Biomedica announced an agreement to potentially make AstraZeneca's COVID-19 vaccine beyond 2022. It has already manufactured more than 100 million doses since 2020.

Oxford Biomedica signs new deal to make AstraZeneca COVID shot

AstraZeneca PLC (LSE:AZN) announced today that it had signed a new three-year agreement with Oxford BioMedica PLC (LSE:OXB) to manufacture the Covid-19 vaccine, amid concerns over the safety of the drug. The Oxford-based company plans to open a new facility to produce AstraZeneca's Covid-19 vaccine called the Oxbox in the last three months of the year and is expected to generate £30mln of revenue from the arrangement.

AstraZeneca secures Covid-19 vaccine production amid safety concerns

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca presented data for IMFINZI® (durvalumab) combinations from the HIMALAYA and TOPAZ-1 Phase III trials at the European Association for the Study of the Liver's International Liver Congress 2022 (EASL 2022) and the European Society for Medical Oncology's World Congress on Gastrointestinal Cancer (ESMO World GI 2022). Exploratory sub-analyses from HIMALAYA and TOPAZ-1 were presented at ESMO World GI 2022, June 29 to July 2 in Barcelona. Additionally, h

AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® (durvalumab) Combinations in Patients With Liver and Biliary Tract Cancers

Nuformix PLC (LSE:NFX) is developing a pre-clinical programme to further assess the potential of NXP004, a reformulation of AstraZeneca blockbuster cancer drug Lynparza. The aim of the work is to come up with a version of the AZ product that is both bioequivalent and 'bio-better' than the existing treatment.

Nuformix hoping to develop a 'bio-better' version of AstraZeneca blockbuster

AbbVie

Bristol-Myers

Johnson & Johnson

Seagen

Novartis

Investors who are sweating the loss of patent protection for some of Big Pharma's top-selling drugs should relax.

News for AstraZeneca Stock (AZN)